Novo Nordisk selling low doses of Ozempic, and Wegovy for $199 for a limited time
Novo Nordisk is now offering people who pay out of pocket a steep discount for select doses of Ozempic and Wegovy.
GLP-1 price war heats up as Novo Nordisk offers $199 starter doses
The company is lowering costs on its blockbuster drugs to fend off competitors, compounding pharmacies, and mounting political pressure. Novo Nordisk, the Danish drug company that makes Ozempic and Wegovy, is now offering the drugs at lower prices for self-pay patients.
Why Employers Still Cover GLP-1 Drugs as Prices Skyrocket
Recent studies show the surging popularity of Ozempic, Wegovy and similar drugs for weight loss is driving employer health coverage costs higher.
A closer look at the unapproved peptide injections promoted by influencers and celebrities
By MATTHEW PERRONE WASHINGTON (AP) — Unapproved peptide drugs have become a trendy new hack among wellness influencers, fitness coaches and celebrities, pitched as a way to build muscle, shed pounds and look younger. Related Articles NIH funding cuts have affected over 74,000 people enrolled in experiments, a new report says Novo cuts Wegovy prices, […]
Novo cuts Wegovy prices, but doctors still see cost challenges for patients
Novo Nordisk is chopping prices again for Wegovy, but doctors say the expense will remain challenging for patients without insurance. The drugmaker said Monday that it has started selling higher doses of the injectable obesity treatment for $349 a month to patients paying the full bill. That’s down from $499, and in line with terms […]
Novo Nordisk lowers self-pay prices for weight loss drugs ahead of Lilly, TrumpRx
Novo Nordisk said Monday it will immediately drop its cash-pay prices for megablockbusters Ozempic and Wegovy to $349 per month, more than six weeks before Eli Lilly’s rival weight loss drug Zepbound is expected to …
Tirzepatide may only temporarily suppress brain ‘food noise’ activity
A rare glimpse into the brain activity of a patient with obesity and loss of control eating on tirzepatide, marketed as Mounjaro and Zepbound, revealed that the medication suppresses signaling in the brain’s “reward center” thought to be involved in food noise—but only temporarily.
Aramark (ARMK) Q4 2025 Earnings Call Transcript
Image source: The Motley Fool. DATE Monday, Nov. 17, 2025 at 8:30 a.m. ET CALL PARTICIPANTS Chief Executive Officer — John J. Zillmer Chief Financial Officer — James Tarangelo Need a quote from a Motley Fool analyst? Email [email protected] RISKS The fourth quarter experienced a revenue shortfall due to significant deferrals in the timing of […]
Survey Reveals Widespread Usage of GLP-1 Drugs
About one in eight American adults are now taking GLP-1 drugs like Ozempic, Wegovy, Zepbound, and Mounjaro, a new survey shows—a sharp increase from just 18 months ago. These medications, approved in the US only four years ago for obesity, are quickly becoming some of the most widely prescribed,…
Lactalis enters the GLP-1 race
